Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The AASM updates its clinical guideline for restless legs syndrome. It recommends against the most popular drugs.
Recent research challenges the conventional understanding of bruxism, suggesting it may serve as a stress release mechanism and could even offer protective benefits against certain disorders.
The 2022 CDC Opioid Prescribing Guidelines released on November 3, 2022, replaced earlier guidelines that had led to confusion, misinterpretation, and faulty application by medical providers, according to a statement from the RLS Foundation.
New York Times: Some experts say tooth-grinding is a behavior rather than a disorder, and the dentist’s chair isn’t the best place to address it.
Mark Boulos launched a large cohort study investigating the relationship between medication classes and periodic limb movements.
The gold-standard assay for measuring orexin deficiency in cerebrospinal fluid requires a lumbar puncture and radioactive materials. New findings could help advance testing alternatives for people with narcolepsy.